AI-Powered Drug Discovery Platforms Are Restructuring the Global Pharmaceutical Pipeline Through 2035

AI-powered drug discovery is crossing from computational promise to clinical reality. Insilico Medicine's rentosertib became the first fully AI-designed drug to complete Phase 2a trials in humans, posting measurable lung function improvement in patients with idiopathic pulmonary fibrosis. Isomorphic Labs, which raised $600 million in March 2025 and holds partnerships with Eli Lilly and Novartis worth nearly $3 billion, is targeting first-in-human trials by end of 2026. The global market for AI-driven drug discovery platforms, valued between $2.9 billion and $6.9 billion in 2025 depending on scope definition, is forecast to grow at CAGRs ranging from 15% to 30% through 2035, driven by clinical validation events, consolidation activity, and tightening FDA oversight of AI development methods.

First AI-Designed Drug Posts Phase 2a Results. The Industry Is Paying Close Attention.

Insilico Medicine's rentosertib, a TNIK kinase inhibitor designed entirely using the company's Pharma.AI platform, completed a Phase 2a study in China for idiopathic pulmonary fibrosis, with results published in Nature Medicine in 2025. Patients in the 60 mg group showed a mean lung function improvement of +98.4 mL versus a decline of 20.3 mL in the placebo arm, with profibrotic biomarkers dropping significantly. Insilico is now targeting Phase 3 by mid-2027. 

The clinical result matters beyond one company. Insilico is currently the only firm in the AI drug discovery field with a Phase 2 readout in humans for a fully AI-discovered, AI-designed asset. That distinction is influencing investor confidence across the sector. Insilico raised $293 million in a Hong Kong IPO in December 2025 and secured a potential $100 million collaboration deal with Eli Lilly.

The Lilly partnership, which includes an equity stake in Insilico, centers on Insilico's Pharma.AI platform, which Insilico and Eli Lilly entered a research collaboration in November 2025 to improve capabilities to identify, design, and optimize candidate compounds targeting molecules.

Isomorphic Labs Targets Human Trials by Year-End, But Timeline Has Shifted

Alphabet subsidiary Isomorphic Labs, the commercial entity built on DeepMind's AlphaFold protein structure prediction work, is advancing the most heavily capitalized pipeline in the field. In March 2025, Isomorphic Labs raised $600 million in a financing round led by Thrive Capital, directed toward developing its next-generation AI drug design engine and advancing programs into clinical development.

Isomorphic also holds partnerships with Novartis and Eli Lilly worth nearly $3 billion in potential value.

The company's clinical timeline has been revised. At the January 2026 World Economic Forum in Davos, CEO Demis Hassabis confirmed that Isomorphic's first clinical trials are now expected by end of 2026, a shift from the 2025 target he had previously communicated. The company has 17 active drug development programs across oncology, immunology, and cardiovascular disease, with its first AI-designed cancer drug set to enter Phase 1 clinical trials by end of 2026.

The revision reflects a practical constraint: computational design timelines are compressible, but regulatory preparation, patient safety review, and IND approval processes are not.

Recursion and Exscientia Merge, Then Restructure

The most consequential consolidation event in the AI drug discovery sector in the past 18 months was the merger of Recursion Pharmaceuticals and Exscientia, which closed in July 2025. The combined company is headquartered across Oxford and Salt Lake City, with a combined valuation of approximately $1.8 billion and estimated 2025 revenues of $150 to $180 million.

The strategic rationale centered on pairing Recursion's biological data infrastructure with Exscientia's generative chemistry capabilities. Recursion gained cutting-edge generative chemistry and several clinical-stage compounds, while Exscientia's programs benefited from Recursion's biological expertise and infrastructure.

Post-merger integration has been uneven. Recursion announced the discontinuation of multiple pipelines in 2025, including clinical candidates that were terminated or out-licensed as part of a strategic restructuring, exposing the structural challenge that while scale has grown, the distance to profitability remains significant.

From a productivity standpoint, Recursion has demonstrated measurable achievements, conducting millions of experiments weekly and securing over $1 billion in potential milestones through collaborations and merger deals. The key challenge lies in translating these advances into patient outcomes, particularly as the merged company anticipates more than 10 clinical readouts by 2025 to 2026.

Capital Is Flowing in Concentrated Bursts

Venture and institutional capital allocation in AI drug discovery in 2025 and early 2026 has been large and selective, concentrated in platforms with differentiated data assets or clinical proof points.

In December 2025, Chai Discovery raised $130 million in a Series B round for its Chai-2 platform, a generative system designed to replace slow iterative experimental screening with computational design, capable of generating novel antibody sequences based on a target without extensive screening.

Xaira Therapeutics, which launched in April 2024 with a seed and Series A funding round exceeding $1 billion from ARCH Venture Partners, Foresite Labs, Sequoia, and Lux Capital, represents the largest single capital deployment in the field's history at that stage.

In January 2025, Novo Nordisk committed to a $2.76 billion partnership with Valo Health to integrate Valo's AI platform into Novo's drug development programs, signaling that large pharma is now writing partnership checks that rival acquisition prices. 

By early 2026, 25 of the first 59 major VC deal highlights tracked in the year were biotech startups, including seven rounds of $100 million or more, reversing a cautious investment posture that had prevailed through much of 2023 and 2024.

FDA Establishes a Regulatory Framework. The Industry Adapts.

The U.S. Food and Drug Administration published draft guidance on AI in drug development in January 2025, establishing a seven-step credibility assessment framework for AI and machine learning models used in drug discovery and development decisions. The FDA is taking AI in drug development seriously, but carefully, and the framework places new documentation and validation burdens on companies seeking to advance AI-nominated candidates into clinical trials.

The regulatory posture reflects growing awareness that AI predictions require experimental validation regardless of model sophistication. Analysts project roughly 60% probability that the first AI-discovered drug receives FDA approval in 2027 or 2028, with Relay Therapeutics' Zovegalisib, already in Phase 3 with Breakthrough Therapy Designation, potentially reaching approval before Insilico's rentosertib.

The FDA's 2023 guidelines on AI in drug development emphasized validation and transparency to ensure model reliability, and the 2025 framework builds on that foundation with more specific evidentiary requirements.

Market Scale: Where the Numbers Stand

Market sizing in AI drug discovery varies substantially across research providers, driven by differing definitions of scope (platforms only versus integrated drug development), geographic boundaries, and inclusion of adjacent data services.

One projection sizes the global AI-driven drug discovery platforms market at $2.9 billion in 2025 and $12.5 billion by 2035, growing at a CAGR of 15.7%, with the machine learning segment accounting for 45% of market share in 2025.

Precedence Research places the market at $6.93 billion in 2025, reaching $16.52 billion by 2034 at a CAGR of 10.10%, with North America holding a 56% share in 2024 and Asia-Pacific projected to grow at a 21.1% CAGR through 2034.

DataM Intelligence estimates the market reached $6.24 billion in 2024 and is expected to reach $34.05 billion by 2033, at a CAGR of 18.5%.

Across projections, directional consensus holds: the market grows at double-digit rates through 2035, oncology is the dominant therapeutic application, pharmaceutical and biotechnology companies account for the largest end-user share, and North America leads regional adoption. The divergence in absolute numbers reflects scope definitions that practitioners should scrutinize before citing.

Where the Competitive Advantage Actually Lives

The technical landscape is consolidating around four differentiated lanes: structure-based foundation models (Isomorphic Labs), generative chemistry and phenomics (Recursion/Exscientia), translational AI and ADMET prediction (Iambic, Genesis Therapeutics), and broad multimodal platforms (Insilico Medicine). No single technical layer constitutes a defensible moat. The advantage is increasingly the integration of proprietary perturbational data, generative models, automated wet labs, and clinical translation infrastructure, with patient-relevant data as the scarce input.

In September 2025, Capgemini partnered with Insilico Medicine to develop what the two companies called Pharmaceutical Superintelligence, an agentic AI system for end-to-end drug discovery workflows from target identification to clinical design, using generative AI and predictive modeling.

In November 2025, Ginkgo Datapoints launched the Virtual Cell Pharmacology Initiative, an open-source platform for standardized virtual cell modeling aimed at testing over 100,000 compounds and generating more than 12 billion data points.

These moves signal that the infrastructure layer of AI drug discovery is becoming more collaborative while the proprietary clinical data layer becomes more contested.

12 to 24 Month Outlook

Three structural shifts will define the AI drug discovery market through mid-2027. First, the sector will receive its first FDA regulatory decision on an AI-nominated clinical candidate, with Relay Therapeutics' Zovegalisib the likeliest near-term outcome. That approval or rejection will function as a market-wide credibility signal affecting funding, partnership valuations, and regulatory posture across all platforms.

Second, Isomorphic Labs' entry into Phase 1 human trials, expected before end of 2026, will test whether structure-prediction-led drug design can generate clinical candidates at scale. The company's $600 million raise and nearly $3 billion in partnership commitments means the market has already priced in significant confidence.

Third, the Recursion/Exscientia integration will reach a decision point. More than 10 clinical readouts are anticipated in the 2025 to 2026 window. Positive data would validate the merger's industrial logic. Continued pipeline discontinuations would accelerate consolidation pressure on the broader mid-tier of the market.

McKinsey estimates AI, particularly generative AI, could contribute $60 to $110 billion annually in pharmaceutical value, primarily through accelerating discovery and development timelines. Whether the sector achieves that scale depends on what the next two years of clinical data confirm.

FAQ

Q1: Which AI drug discovery platform is furthest along in clinical trials?
Insilico Medicine's rentosertib is the most clinically advanced asset produced by a fully AI-driven pipeline. It completed a Phase 2a study in China for idiopathic pulmonary fibrosis, with patients in the 60 mg group showing a mean lung function improvement of +98.4 mL compared to a decline of 20.3 mL in the placebo arm. Insilico is now targeting Phase 3 by mid-2027.

Q2: Has any AI-discovered drug received FDA approval?
As of 2026, no AI-discovered drug has received FDA approval. Analysts project approximately 60% probability that the first approval occurs in 2027 or 2028, with Relay Therapeutics' Zovegalisib, currently in Phase 3 with Breakthrough Therapy Designation, as the nearest candidate.

Q3: What is the global AI drug discovery market size in 2025?
Estimates vary by scope. Precedence Research values the market at $6.93 billion in 2025, while other projections place AI-driven drug discovery platforms specifically at $2.9 billion in 2025. All major sources project double-digit CAGRs through 2035, with North America as the largest regional market.

Q4: How is the FDA regulating AI in drug discovery?
The FDA released draft guidance in January 2025 establishing a seven-step credibility assessment framework for AI and machine learning models used in drug development. The agency is approaching AI in drug development carefully, placing validation and documentation requirements on companies advancing AI-nominated candidates into clinical trials.

Q5: What drove the Recursion and Exscientia merger?
Recursion gained generative chemistry capabilities and clinical-stage compounds from Exscientia, while Exscientia's programs benefited from Recursion's biological data infrastructure. The goal was to industrialize drug discovery by combining both companies' AI capabilities with biological expertise. The merged entity has a combined valuation of approximately $1.8 billion as of 2025.

Access Deeper Intelligence on This Market

The developments covered in this article are analyzed in depth in Dimension Market Research's report on the AI in Drug Discovery Market, covering platform segmentation, competitive positioning, regional forecasts, regulatory frameworks, and investment trend analysis through 2035. Organizations evaluating platform partnerships, pipeline investments, or competitive strategy in AI-enabled pharmaceutical R&D can access the full report and speak with DMR analysts at dimensionmarketresearch.com.